OBJECTIVE: To examine agreement between self-reported exposure to lipid-lowering medications and objective evidence of filling prescribed lipid-lowering medications. STUDY DESIGN AND SETTING: Using data from 7,918 adults from the Adverse Childhood Experiences (ACE) Study, we calculated the sensitivity, specificity, and positive (PV+) and negative (PV-) predictive values, and likelihood ratios for self-reported exposure to lipid-lowering medications compared to exposure obtained from pharmacy claims (gold standard) both overall and by age, sex, race/ethnicity, education, and ACE Score. RESULTS: Eight percent (n=655) of adults self-reported lipid-lowering medication exposure, and 379 adults filled at least one lipid-lowering prescription within 60 days of the baseline exam during 1997. The sensitivity of self-reported exposure was nearly 94%; the specificity was 96%; the PV+ was 54%; and the PV- was nearly 100%. Values for sensitivity, specificity, PV+, and PV- were similar across participant characteristics. CONCLUSION: A self-reported measure of lipid-lowering medication exposure was accurate with high sensitivity and specificity while the PV+ of self-reported lipid-lowering medication exposure was relatively low. These findings suggest that self-reported exposure to lipid-lowering medications may be useful in surveys that examine the prevalence of hyperlipidemia, but may overestimate actual exposure in studies monitoring trends in use of lipid-lowering medications.
OBJECTIVE: To examine agreement between self-reported exposure to lipid-lowering medications and objective evidence of filling prescribed lipid-lowering medications. STUDY DESIGN AND SETTING: Using data from 7,918 adults from the Adverse Childhood Experiences (ACE) Study, we calculated the sensitivity, specificity, and positive (PV+) and negative (PV-) predictive values, and likelihood ratios for self-reported exposure to lipid-lowering medications compared to exposure obtained from pharmacy claims (gold standard) both overall and by age, sex, race/ethnicity, education, and ACE Score. RESULTS: Eight percent (n=655) of adults self-reported lipid-lowering medication exposure, and 379 adults filled at least one lipid-lowering prescription within 60 days of the baseline exam during 1997. The sensitivity of self-reported exposure was nearly 94%; the specificity was 96%; the PV+ was 54%; and the PV- was nearly 100%. Values for sensitivity, specificity, PV+, and PV- were similar across participant characteristics. CONCLUSION: A self-reported measure of lipid-lowering medication exposure was accurate with high sensitivity and specificity while the PV+ of self-reported lipid-lowering medication exposure was relatively low. These findings suggest that self-reported exposure to lipid-lowering medications may be useful in surveys that examine the prevalence of hyperlipidemia, but may overestimate actual exposure in studies monitoring trends in use of lipid-lowering medications.
Authors: Marianne Haapea; Jouko Miettunen; Sari Lindeman; Matti Joukamaa; Hannu Koponen Journal: Int J Methods Psychiatr Res Date: 2010-06 Impact factor: 4.035
Authors: Timothy S Anderson; Bocheng Jing; Charlie M Wray; Sarah Ngo; Edison Xu; Kathy Fung; Michael A Steinman Journal: Med Care Date: 2019-10 Impact factor: 2.983
Authors: Dylan L Steen; Irfan Khan; Laura Becker; JoAnne M Foody; Katherine Gorcyca; Robert J Sanchez; Robert P Giugliano Journal: Clin Cardiol Date: 2016-12-27 Impact factor: 2.882
Authors: Matthew D Olson; Gretchen L Tong; Beat D Steiner; Anthony J Viera; Evan Ashkin; Warren P Newton Journal: BMC Fam Pract Date: 2012-08-13 Impact factor: 2.497